ストックスクリーナーアプリを入手
40.98
0.86%
0.35
前日終値:
$40.63
開ける：
$41
24時間の取引高:
1.00M
Relative Volume:
0.79
時価総額：
$3.00B
収益：
当期純損益:
$-98.78M
株価収益率:
-24.63
EPS:
-1.6638
ネットキャッシュフロー:
$-65.60M
1週間 パフォーマンス:
-12.75%
1か月 パフォーマンス:
-28.67%
6か月 パフォーマンス:
-10.11%
1年 パフォーマンス:
+92.48%
1日の値動き範囲:
$40.29
$42.06
1週間の範囲:
$39.25
$46.94
52週間の値動き範囲:
$14.79
$62.32
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Compare ELVN vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
40.98 | 3.00B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-02 | 開始されました | Morgan Stanley | Overweight |
| 2026-10-01 | 開始されました | JP Morgan | Overweight |
| 2026-08-18 | 開始されました | Barclays | Overweight |
| 2026-08-18 | 開始されました | William Blair | Outperform |
| 2026-06-09 | 開始されました | Stifel | Buy |
| 2026-05-12 | 開始されました | Guggenheim | Buy |
| 2025-06-16 | 開始されました | Goldman | Buy |
| 2024-12-13 | 開始されました | BTIG Research | Buy |
| 2024-09-09 | 開始されました | H.C. Wainwright | Buy |
| 2024-06-11 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-09 | 開始されました | Mizuho | Buy |
| 2023-03-29 | 開始されました | Jefferies | Buy |
すべてを表示
Enliven Therapeutics Inc (ELVN) 最新ニュース
After exercising options at $15.47, Enliven Therapeutics (ELVN) director sells 13,000 shares. - Stock Titan
Director Jeffrey Garland proposes selling 13,000 Enliven Therapeutics (NASDAQ: ELVN) shares. - stocktitan.net
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock - Investing.com
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares - Stock Titan
Enliven Therapeutics (Nasdaq:ELVN)Stock Analysis - Simply Wall Street
Enliven Therapeutics (ELVN) officer lines up new stock sale - Stock Titan
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
Enliven's Morgan Stanley conference chat will be webcast Sept. 16 - Stock Titan
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics to Present at Upcoming Investor Conferences - finance.yahoo.com
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting - PR Newswire
Enliven will present leukemia drug data twice at a Houston meeting - Stock Titan
Discipline and Rules-Based Execution in ELVN Response - Stock Traders Daily
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting - Intellectia AI
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - kalkine.ca
Enliven (ELVN) Earnings Snapshot: EPS Falls Short of Its Estimate in the Reported Period; Share Response: The Stock Records a 0.79% Decrease on the DayProfit Cycle Analysis - vinanet.vn
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl Executes Two Stock Sales on August 17 Under 10b5-1 Plan - Kalkine Media
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan - Stock Titan
Enliven Therapeutics (ELVN) CMO exercises options, sells stock - Stock Titan
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - Moomoo
Enliven Therapeutics CMO Helen Louise Collins Executes Stock Option and Sells 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
What's Going On With Enliven Therapeutics Stock Tuesday?Enliven Therapeutics (NASDAQ:ELVN) - Benzinga
Enliven a new outperform at Barclays on potential of CML asset - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at William Blair - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho - MarketBeat
William Blair Initiates Enliven Therapeutics at Outperform - marketscreener.com
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com India
William Blair initiates Enliven Therapeutics stock with outperform rating By Investing.com - Investing.com UK
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com Canada
Barclays initiates Enliven Therapeutics stock at Overweight, $78 PT By Investing.com - Investing.com UK
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC - MarketBeat
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82 - Moomoo
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN - MarketBeat
FMR LLC Boosts Stake in Enliven Therapeutics Inc (ELVN) with Str - GuruFocus
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics Inc (ELVN) 財務データ
収益
当期純利益
現金流量
EPS
Enliven Therapeutics Inc (ELVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| JEFFREY GARLAND | Director |
Oct 01 '26 |
Proposed Sale |
46.67 |
13,000 |
606,719 |
0 |
| Garland J. Scott | Director |
Oct 01 '26 |
Sale |
46.67 |
13,000 |
606,719 |
0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Option Exercise |
2.48 |
5,000 |
12,400 |
30,000 |
| Hohl Benjamin | Officer |
Sep 17 '26 |
Proposed Sale |
49.12 |
12,036 |
591,208 |
0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Sep 17 '26 |
Sale |
50.35 |
5,000 |
251,754 |
25,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 17 '26 |
Sale |
50.35 |
6,018 |
303,003 |
38,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Sep 17 '26 |
Option Exercise |
14.85 |
3,982 |
59,133 |
44,018 |
| Heyman Richard A. | resigned from BOD |
Sep 04 '26 |
Proposed Sale |
59.28 |
38,000 |
2,252,830 |
0 |
| Collins Helen Louise | CHIEF MEDICAL OFFICER |
Aug 17 '26 |
Sale |
58.59 |
5,000 |
292,931 |
25,000 |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER |
Aug 17 '26 |
Sale |
58.58 |
6,018 |
352,551 |
40,036 |
1.65%
大文字化:
|
ボリューム (24 時間):